<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37249667</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>3429</StartPage><EndPage>3442</EndPage><MedlinePgn>3429-3442</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-023-06869-8</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The study aims to increase understanding of edaravone's efficacy and safety as an amyotrophic lateral sclerosis (ALS) treatment and provide significant insights regarding this field's future research.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a comprehensive search of the Embase, PubMed, Cochrane Library, Web of Science, and Scopus databases for randomized controlled trials and observational studies up until September 2022. We evaluated the studies' quality using the Cochrane risk of bias tool and the National Institutes of Health tool.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 11 studies with 2845 ALS patients. We found that edaravone improved the survival rate at 18, 24, and 30&#xa0;months (risk ratio (RR)&#x2009;=&#x2009;1.03, 95% confidence interval (CI) [1.02 to 1.24], P&#x2009;=&#x2009;0.02), (RR&#x2009;=&#x2009;1.22, 95% CI [1.06 to 1.41], P&#x2009;=&#x2009;0.007), and (RR&#x2009;=&#x2009;1.17, 95% CI [1.01 to 1.34], P&#x2009;=&#x2009;0.03), respectively. However, the administration of edaravone did not result in any significant difference in adverse effects or efficacy outcomes between the two groups, as indicated by a P value greater than 0.05.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Edaravone improves survival rates of ALS patients at 18, 24, and 30&#xa0;months with no adverse effects. However, edaravone does not affect functional outcomes. In order to ensure the validity of our findings and assess the results in accordance with the disease stage, it is essential to carry out additional prospective, rigorous, and high-quality clinical trials. The current study offers preliminary indications regarding the effectiveness and safety of edaravone. However, further comprehensive research is required to establish the generalizability and sustainability of the findings.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Nourelden</LastName><ForeName>Anas Zakarya</ForeName><Initials>AZ</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Al-Azhar University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kamal</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Al-Azhar University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagrass</LastName><ForeName>Abdulrahman Ibrahim</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0002-0297-9385</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Al-Azhar University, Cairo, Egypt. Abdulrahmanelsayed.stu.3@azhar.edu.eg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tawfik</LastName><ForeName>Abdelrahman G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Pharmacotherapy, College of Pharmacy, The University of Utah, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elhady</LastName><ForeName>Mahmoud M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Benha University, Qalubiya, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fathallah</LastName><ForeName>Ahmed Hashem</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Minia University, Minia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eshag</LastName><ForeName>Mona Muhe Eldeen</ForeName><Initials>MME</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Bahri, Khartoum, Sudan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaazouee</LastName><ForeName>Mohamed Sayed</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Al-Azhar University, Assiut, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Edaravone</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>30</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>30</Day><Hour>11</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37249667</ArticleId><ArticleId IdType="pmc">PMC10495275</ArticleId><ArticleId IdType="doi">10.1007/s10072-023-06869-8</ArticleId><ArticleId IdType="pii">10.1007/s10072-023-06869-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brotman RG, Moreno-Escobar MC, Joseph J et al (2022) Amyotrophic lateral sclerosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556151/</Citation><ArticleIdList><ArticleId IdType="pubmed">32310611</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond J, Oskarsson B, Mehta P, Horton K. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010&#x2013;2015. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5&#x2013;6):413&#x2013;420. doi: 10.1080/21678421.2019.1612435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1612435</ArticleId><ArticleId IdType="pmc">PMC6946020</ArticleId><ArticleId IdType="pubmed">31131638</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Liu T, Liu L, Yao X, Chen L, Fan D, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020;267(4):944&#x2013;953. doi: 10.1007/s00415-019-09652-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09652-y</ArticleId><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Raymond J, Punjani R, Han M, Larson T, Kaye W, et al. Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies. Amyotroph Lateral Scler Frontotemporal Degener. 2017;2022:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9568617</ArticleId><ArticleId IdType="pubmed">35422180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera LC, Nigel LP. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4(1):3. doi: 10.1186/1750-1172-4-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-4-3</ArticleId><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5&#x2013;6):310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Achtert K, Kerkemeyer L. The economic burden of amyotrophic lateral sclerosis: a systematic review. Eur J Health Econ. 2021;22(8):1151&#x2013;1166. doi: 10.1007/s10198-021-01328-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10198-021-01328-7</ArticleId><ArticleId IdType="pubmed">34143346</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell. 2011;147(3):498&#x2013;508. doi: 10.1016/j.cell.2011.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.10.011</ArticleId><ArticleId IdType="pmc">PMC3220614</ArticleId><ArticleId IdType="pubmed">22036560</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10(3):253&#x2013;263. doi: 10.1016/S1474-4422(11)70015-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxid Med Cell Longev. 2017;2017:2525967. doi: 10.1155/2017/2525967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/2525967</ArticleId><ArticleId IdType="pmc">PMC5529664</ArticleId><ArticleId IdType="pubmed">28785371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo L, Zhou T, Pannell BK, Ziegler AC, Best TM. Biological and physiological role of reactive oxygen species&#x2014;the good, the bad and the ugly. Acta Physiol (Oxf) 2015;214(3):329&#x2013;348. doi: 10.1111/apha.12515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.12515</ArticleId><ArticleId IdType="pubmed">25912260</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH., Jr Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol. 1997;42(4):644&#x2013;654. doi: 10.1002/ana.410420416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410420416</ArticleId><ArticleId IdType="pubmed">9382477</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD. Moore DH 2012 Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012;3:Cd001447.</Citation><ArticleIdList><ArticleId IdType="pubmed">11687111</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujisawa A, Yamamoto Y. Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone. Redox Rep. 2016;21(3):98&#x2013;103. doi: 10.1179/1351000215Y.0000000025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1351000215Y.0000000025</ArticleId><ArticleId IdType="pmc">PMC6837651</ArticleId><ArticleId IdType="pubmed">26196041</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, Ito H, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213(2):448&#x2013;455. doi: 10.1016/j.expneurol.2008.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.07.017</ArticleId><ArticleId IdType="pubmed">18718468</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Song Z, Li X, Huiwang, Zeng Y, Qinwang et al (2019) Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis. Neurol Sci 40(2):235-41</Citation><ArticleIdList><ArticleId IdType="pubmed">30483992</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7&#x2013;8):610&#x2013;617. doi: 10.3109/21678421.2014.959024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing group; Edaravone (MCI-186) ALS 18 study group (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing group; Edaravone (MCI-186) ALS 19 study group. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):40&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">28872915</ArticleId></ArticleIdList></Reference><Reference><Citation>Eishi-Oskouei A, Basiri K. Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: A parallel-group single-blind trial. Curr J Neurology. 2021;20(1):1.</Citation></Reference><Reference><Citation>Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study) Amyotroph Lateral Scler. 2006;7(4):241&#x2013;245. doi: 10.1080/17482960600881870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016;21(3):104&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6837462</ArticleId><ArticleId IdType="pubmed">26191780</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2022) Cochrane handbook for systematic reviews of interventions version 6.3. Cochrane, available from https://www.training.cochrane.org/handbook</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu M, Tortorice K, Zacher J, Dong D, Hur K, Zhang R, et al. 2020 Assessment of use and safety of edaravone for amyotrophic lateral sclerosis in the veterans affairs health care system. JAMA Netw Open. 2020;3(10):e2014645-e. doi: 10.1001/jamanetworkopen.2020.14645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.14645</ArticleId><ArticleId IdType="pmc">PMC7536587</ArticleId><ArticleId IdType="pubmed">33017028</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. J Clin Epidemiol. 2013;66(7):736&#x2013;42. doi: 10.1016/j.jclinepi.2013.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2013.02.004</ArticleId><ArticleId IdType="pubmed">23623694</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Berry JD, Ciepielewska M, Liu Y, Zambrano GS, Zhang J, et al. Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis. EClinicalMedicine. 2022;52:101590. doi: 10.1016/j.eclinm.2022.101590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101590</ArticleId><ArticleId IdType="pmc">PMC9358426</ArticleId><ArticleId IdType="pubmed">35958519</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel S, Maier A, Steinbach R, Grosskreutz J, Koch JC, Sarikidi A, et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79(2):121&#x2013;130. doi: 10.1001/jamaneurol.2021.4893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.4893</ArticleId><ArticleId IdType="pmc">PMC8749709</ArticleId><ArticleId IdType="pubmed">35006266</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortuna A, Gizzi M, Bello L, Martinelli I, Bertolin C, Pegoraro E, et al. Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. J Neurol Sci. 2019;404:47&#x2013;51. doi: 10.1016/j.jns.2019.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.06.006</ArticleId><ArticleId IdType="pubmed">31325668</ArticleId></ArticleIdList></Reference><Reference><Citation>Houzen H, Kano T, Horiuchi K, Wakita M, Nagai A, Yabe I. Improved long-term survival with edaravone therapy in patients with amyotrophic lateral sclerosis: A retrospective single-center study in japan. Pharmaceuticals. 2021;14(8):705. doi: 10.3390/ph14080705.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14080705</ArticleId><ArticleId IdType="pmc">PMC8398196</ArticleId><ArticleId IdType="pubmed">34451802</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Moglia C, Lizio A, Caponnetto C, Dubbioso R, Giannini F, et al. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020;267(11):3258&#x2013;3267. doi: 10.1007/s00415-020-09993-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09993-z</ArticleId><ArticleId IdType="pubmed">32556567</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, Yamashita S, Ueyama H, Ishizaki M, Maeda Y, Ando Y. Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. ENeurologicalSci. 2018;11:11&#x2013;14. doi: 10.1016/j.ensci.2018.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.05.001</ArticleId><ArticleId IdType="pmc">PMC6006910</ArticleId><ArticleId IdType="pubmed">29928711</ArticleId></ArticleIdList></Reference><Reference><Citation>Couratier P, Corcia P, Lautrette G, Nicol M, Preux PM, Marin B. Epidemiology of amyotrophic lateral sclerosis: a review of literature. Rev Neurol (Paris) 2016;172(1):37&#x2013;45. doi: 10.1016/j.neurol.2015.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2015.11.002</ArticleId><ArticleId IdType="pubmed">26727307</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169(1-2):13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailly C. Potential use of edaravone to reduce specific side effects of chemo-, radio- and immuno-therapy of cancers. Int Immunopharmacol. 2019;77:105967. doi: 10.1016/j.intimp.2019.105967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2019.105967</ArticleId><ArticleId IdType="pubmed">31670091</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>